MDT · News · 20261016N

Products and Technology

Medtronic plc · 2026-10-16 · Importance 25 · Surprise 30

Medtronic is expanding in cardiac ablation, robotics and structural heart, identifying these areas as high-growth markets. Hypertension therapy is receiving support from improved reimbursement, clinical evidence, hospital adoption and workflow integration. MedSurg growth is being supported by robotic surgery, digital surgery and core procedural technologies, with Hugo and Touch Surgery increasing adoption.

Key facts

• Medtronic plc EVP Michael Marinaro sold 10,420 ordinary shares at $96 per share on October 15, 2026 under a Rule 10b5-1 trading plan adopted in March 2026. source
• Medtronic plc's earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.76%. source
• After the October 15, 2026 sale, Michael Marinaro directly holds 105,916 ordinary shares of Medtronic plc. source
• The Form 4 filing states the Rule 10b5-1 plan was adopted on March 17, 2026. source
• Medtronic plc is increasing focus on hypertension aided by improved reimbursement, clinical evidence, hospital adoption and workflow integration. source
• Medtronic plc's MedSurg growth is supported by robotics, digital surgery and core procedural technologies. source
• Medtronic plc's Hugo and Touch Surgery are expanding adoption. source
• Medtronic plc's stock rose 0.1% over the past year versus the industry's 26.6% fall and the S&P 500 composite's 16.6% jump. source